Amyloid-β mediates intestinal dysfunction and enteric neurons loss in Alzheimer's disease transgenic mouse.
Guoqiang LiuQuntao YuHouze ZhuBo TanHongyan YuXinyan LiYouming LuHao LiPublished in: Cellular and molecular life sciences : CMLS (2023)
Alzheimer's disease (AD) is traditionally considered as a brain disorder featured by amyloid-β (Aβ) deposition. The current study on whether pathological changes of AD extend to the enteric nervous system (ENS) is still in its infancy. In this study, we found enteric Aβ deposition, intestinal dysfunction, and colonic inflammation in the young APP/PS1 mice. Moreover, these mice exhibited cholinergic and nitrergic signaling pathways damages and enteric neuronal loss. Our data show that Aβ42 treatment remarkably affected the gene expression of cultured myenteric neurons and the spontaneous contraction of intestinal smooth muscles. The intra-colon administration of Aβ42 induced ENS dysfunction, brain gliosis, and β-amyloidosis-like changes in the wild-type mice. Our results suggest that ENS mirrors the neuropathology observed in AD brains, and intestinal pathological changes may represent the prodromal events, which contribute to brain pathology in AD. In summary, our findings provide new opportunities for AD early diagnosis and prevention.
Keyphrases
- wild type
- gene expression
- oxidative stress
- white matter
- resting state
- high fat diet induced
- cerebral ischemia
- signaling pathway
- dna methylation
- type diabetes
- endothelial cells
- functional connectivity
- multiple sclerosis
- body mass index
- high glucose
- electronic health record
- drug induced
- middle aged
- insulin resistance
- adipose tissue
- brain injury
- weight loss
- replacement therapy
- epithelial mesenchymal transition
- multiple myeloma
- smooth muscle
- endoplasmic reticulum stress
- mild cognitive impairment